104 related articles for article (PubMed ID: 16446310)
21. Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53.
Seo J; Chung YS; Sharma GG; Moon E; Burack WR; Pandita TK; Choi K
Oncogene; 2005 Dec; 24(55):8176-86. PubMed ID: 16261166
[TBL] [Abstract][Full Text] [Related]
22. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells.
Xu X; Weaver Z; Linke SP; Li C; Gotay J; Wang XW; Harris CC; Ried T; Deng CX
Mol Cell; 1999 Mar; 3(3):389-95. PubMed ID: 10198641
[TBL] [Abstract][Full Text] [Related]
23. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
24. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform.
Cao L; Li W; Kim S; Brodie SG; Deng CX
Genes Dev; 2003 Jan; 17(2):201-13. PubMed ID: 12533509
[TBL] [Abstract][Full Text] [Related]
25. Functional interplay of p53 and Mus81 in DNA damage responses and cancer.
Pamidi A; Cardoso R; Hakem A; Matysiak-Zablocki E; Poonepalli A; Tamblyn L; Perez-Ordonez B; Hande MP; Sanchez O; Hakem R
Cancer Res; 2007 Sep; 67(18):8527-35. PubMed ID: 17875692
[TBL] [Abstract][Full Text] [Related]
26. Telomere-driven karyotypic complexity concurs with p16INK4a inactivation in TP53-competent immortal endothelial cells.
Wen VW; Wu K; Baksh S; Hinshelwood RA; Lock RB; Clark SJ; Moore MA; Mackenzie KL
Cancer Res; 2006 Nov; 66(22):10691-700. PubMed ID: 17108106
[TBL] [Abstract][Full Text] [Related]
27. Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres.
Benetti R; García-Cao M; Blasco MA
Nat Genet; 2007 Feb; 39(2):243-50. PubMed ID: 17237781
[TBL] [Abstract][Full Text] [Related]
28. Specific subtelomere loss on chromosome der(11)t(3;11)(q23;q23)x2 in anaplastic thyroid cancer cell line OCUT-1.
Kammori M; Onoda N; Nakamura K; Izumiyama N; Ogisawa K; Kurabayashi R; Ogawa T; Kaminishi M; Poon SS; Takubo K
Int J Mol Med; 2006 Jul; 18(1):9-16. PubMed ID: 16786150
[TBL] [Abstract][Full Text] [Related]
29. Telomeric aggregates and end-to-end chromosomal fusions require myc box II.
Caporali A; Wark L; Vermolen BJ; Garini Y; Mai S
Oncogene; 2007 Mar; 26(10):1398-406. PubMed ID: 16953226
[TBL] [Abstract][Full Text] [Related]
30. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects.
Evers B; Jonkers J
Oncogene; 2006 Sep; 25(43):5885-97. PubMed ID: 16998503
[TBL] [Abstract][Full Text] [Related]
31. X inactive-specific transcript RNA coating and genetic instability of the X chromosome in BRCA1 breast tumors.
Vincent-Salomon A; Ganem-Elbaz C; Manié E; Raynal V; Sastre-Garau X; Stoppa-Lyonnet D; Stern MH; Heard E
Cancer Res; 2007 Jun; 67(11):5134-40. PubMed ID: 17545591
[TBL] [Abstract][Full Text] [Related]
32. Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II.
Schoeftner S; Blasco MA
Nat Cell Biol; 2008 Feb; 10(2):228-36. PubMed ID: 18157120
[TBL] [Abstract][Full Text] [Related]
33. BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
Piek JM; Dorsman JC; Massuger LF; Ansink AC; Weegenaar J; Shvarts A; Kenemans P; Verheijen RH
Arch Gynecol Obstet; 2006 Oct; 274(6):327-31. PubMed ID: 16826413
[TBL] [Abstract][Full Text] [Related]
34. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Quaresima B; Faniello MC; Baudi F; Crugliano T; Di Sanzo M; Cuda G; Costanzo F; Venuta S
Oncol Rep; 2006 Oct; 16(4):811-5. PubMed ID: 16969499
[TBL] [Abstract][Full Text] [Related]
35. A novel domain of BRCA1 interacts with p53 in breast cancer cells.
Buck M
Cancer Lett; 2008 Sep; 268(1):137-45. PubMed ID: 18501503
[TBL] [Abstract][Full Text] [Related]
36. Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity.
Kasiappan R; Shih HJ; Chu KL; Chen WT; Liu HP; Huang SF; Choy CO; Shu CL; Din R; Chu JS; Hsu HL
Mol Cancer Res; 2009 Apr; 7(4):536-48. PubMed ID: 19372582
[TBL] [Abstract][Full Text] [Related]
37. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.
Smolen GA; Muir B; Mohapatra G; Barmettler A; Kim WJ; Rivera MN; Haserlat SM; Okimoto RA; Kwak E; Dahiya S; Garber JE; Bell DW; Sgroi DC; Chin L; Deng CX; Haber DA
Cancer Res; 2006 Apr; 66(7):3452-5. PubMed ID: 16585167
[TBL] [Abstract][Full Text] [Related]
38. IL-7Rα deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis.
Kibe R; Zhang S; Guo D; Marrero L; Tsien F; Rodriguez P; Khan S; Zieske A; Huang J; Li W; Durum SK; Iwakuma T; Cui Y
Cell Death Differ; 2012 Jul; 19(7):1139-51. PubMed ID: 22281704
[TBL] [Abstract][Full Text] [Related]
39. A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.
Triplett AA; Montagna C; Wagner KU
Neoplasia; 2008 Dec; 10(12):1325-34. PubMed ID: 19048111
[TBL] [Abstract][Full Text] [Related]
40. BRCA1: a scaffold for p53 response?
Hohenstein P; Giles RH
Trends Genet; 2003 Sep; 19(9):489-94. PubMed ID: 12957542
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
